A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
for Leukemia, Juvenile Myelomonocytic
Drug: Trametinib
Sites in Indianapolis +18 more locations
Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
Sex: All·Age: 1 Month - 21
Code: NCT05849662·Phase 1, Phase 2·Recruiting·Listed May 2023